Depomed, Inc. to Announce Third Quarter 2009 Financial Results on October 29, 2009

• Press Release
• Source: Depomed, Inc.
• On 4:30 pm EDT, Thursday October 22, 2009

MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO - News) announced today that it will release third quarter 2009 financial results after the market closes Thursday, October 29, 2009. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results.

Related Quotes

Symbol	Price	Change
DEPO	3.35	+0.05

{"s" : "depo","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The conference call will also be available via a live webcast on the investor relations section of Depomed’s website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company’s website for three months.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Solvay Pharmaceuticals. A New Drug Applications for DM-1796 is expected to be filed with the FDA in the first quarter of 2010. Product candidate Serada^TM is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA^(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform^(R) drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website, www.depomed.com.

Depomed, Inc.
Sheilah Serradell, 650-462-5900
sserradell@depomed.com